The current best evidence of systemic treatment for plaque psoriasis

( views:, downloads: )
Author:
CHEN Sheng-li()
SUN Jian-fang()
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 33, Issue 02, 2007
DOI:
Key Word:

Abstract:

  • [1]管红珍,彭智聪,付鹰.循证医学中文献证据等级标准的系统性综述药物流行学杂志,2002,11(3):145-148.
  • [2]Lebwohl M.Psoriasis.Lancet,2003,361(9364):1197-1204.
  • [3]Griffiths CE,Clark CM,Chalmers RJ,et al.A systematic review of treatments for severe psonasts.Health Technol Assess.2000.4(40):1-125.
  • [4]Heydendael VM,Spuls PI,Opmeer BC,et al.Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.N Engl J Med.2003.349(7):658-665.
  • [5]Faerber L,Braeutigam M,Weidinger G,et al.Cyclosporine in severe psoriasis.Results of a meta-analysis in 579 patients.Am J Clin Dermatol.2001.2(1):41-47.
  • [6]Ohtsuki M,Nakagawa H,Sugai J,et al.Long-term continuous versus intermittent cyclosporin:therapy for psoriasis.J Derrnatol,2003,30(4):290-298.
  • [7]Spuls PI,Witkamp L,Bossuyt PM,et al.A systematic review of five systemic treatments for severe psoriasis.Br J Dermatol,1997,137(6):943-949.
  • [8]Ellis CN,Krueger GG.Alefacept Clinical Study Group.Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.N Engl J Med,2001,345(4):248-255.
  • [9]Krueger GG,Papp KA,Stough DB,et al.A randomized,double-blind,placebo-controlled phase Ⅲ study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.J Am Acad Dermat.2002.47(6):821-833.
  • [10]Ortonne JP.Clinical response to alefacept:results of a phase 3study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.J Eur Acad Dermatol Venereol,2003.17(Suppl 2):12-16.
  • [11]Lebwohl M,Tyring SK,Hamilton TK,et al.A novel targeted T-cell modulator,efalizumab,for plaque psoriasis.N Engl J Med,2003.349(21):2004-2013.
  • [12]Leonardi CL,Papp KA,Gordon KB,et al.Extended efalizumab therapy improves chronic plaque psoriasis:results from a randomized phase IlI trial.J Am Acad Dermatol.2005.52(3 Pt 1):425-433.
  • [13]Menter A,Gordon K,Carey W,et al.Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.Arch Dermatol.2005.141(1):31-38.
  • [14]Gottlieb AB,Matheson RT,Lowe N,et al.A randomized trial of etanercept as monotherapy for psoriasis.Arch Dermatol,2003,139(12):1627-1632.
  • [15]Leonardi CL,Powers JL,Matheson RT,et al.Etanercept as monotherapy in patients with psoriasis N Engl J Med,2003,349(21):2014-2022.
  • [16]Papp KA,Tyring S,Lahfa M,et al.A global phase Ⅲ randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction.Br J Dermatol.2005.152(6):1304-1312.
  • [17]Tyring S,Gottlieb A,Papp K,et al.Etanercept and clinical outcomes,fatigue,and depression in psoriasis:double-blind placebo-controlled randomised phase Ⅲ trial.Lancet,2006,367(9504):29-35.
  • [18]Chaudhari U,Romano P,Mulcahy LD,et al.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomisedtrial.Lancet.2001.357(9271):1842-1847.
  • [19]Gottlieb AB,Evans R,Li S,et al.Infliximab induction therapy for patients with severe plaque-type psoriasis:a randomized,double-blind,placebo-controlled trial.J Am Acad Dermatol,2004.51(4):534-542.
  • [20]Reich K,Nestle FO,Papp K,et al.Infliximab induction and maintenance therapy for moderate-to-severe psoriasis:a phase Ⅲ,multicentre,double-blind trial.Lancet,2005,366(9494):1367-1374.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn